Cover Image
市場調查報告書

美國的學名藥市場:產業趨勢,競爭環境,市場機會,未來展望

US Generic Drug Market - Industry Trends, Competitive Landscape, Opportunities and Outlook

出版商 IMARC Services Pvt. Ltd. 商品編碼 359386
出版日期 內容資訊 英文 72 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的學名藥市場:產業趨勢,競爭環境,市場機會,未來展望 US Generic Drug Market - Industry Trends, Competitive Landscape, Opportunities and Outlook
出版日期: 2016年05月25日 內容資訊: 英文 72 Pages
簡介

美國的學名藥市場在這年來達到激烈的變化。過去僅佔處方藥整體市場的20%以下,但現在已佔其大半。主要的市場推動要素有學名藥和品牌藥的巨大價差、暢銷藥物的專利到期,老年人口的增加,慢性疾病的蔓延等。

本報告提供美國國內學名藥市場相關分析,提供您學名藥市場結構和成長推動因素,全球及美國的學名藥市場趨勢(實際成果值·預測值),相關法規,市場競爭結構·趨勢,及企業簡介等相關之調查資訊。

第1章 分析方法和市場定義

第2章 分析概要

第3章 美國的學名藥市場:概論

  • 學名藥是什麼?
  • 無名商標/品牌·學名藥
  • 認證學名藥
  • 一般/特殊學名藥

第4章 為何美國的學名藥市場向心力高

  • 暢銷藥物的專利到期
  • 學名藥和新藥的價差
  • 政府·第三方付款人 (Third Party Payers)的預算削減
  • 對學名藥的籌備·處方的獎勵
  • 醫療費給付和自我負擔金的降低
  • 生技仿製藥

第5章 全球學名藥市場

  • 過去·目前市場趨勢
  • 各國市場明細:美國是全球最大的學名藥市場
  • 市場未來預測
  • 最大量開於處方的非專利/品牌醫藥品

第6章 美國的學名藥市場

  • 醫藥品市場:過去、現在、未來的市場趨勢
  • 醫藥品市場:品牌/學名藥的市場佔有率
  • 學名藥市場:過去、現在、未來的市場規模趨勢
  • 學名藥市場:過去、現在、未來的銷售額趨勢
  • 學名藥市場:各部門的市場明細

第7章 美國的學名藥市場:競爭環境

  • 競爭結構
  • 主要企業的銷售額的明細
  • 主要企業的市場規模的明細
  • 最大量開於處方的學名藥
  • 各銷售管道的市場明細
  • 價格趨勢

第8章 美國的學名藥市場:價值鏈分析

  • 研究開發 (R&D)
  • 製造
  • 行銷·流通

第9章 美國的學名藥產業相關法規

  • 醫藥品相關的法規概要
  • 醫藥品的認證申請
  • 專利及市場壟斷權
  • 學名藥法規上的要件
  • 升降口·蠟男人法 (Hatch-Waxman Act)
  • 認證制度
  • 其他的重要考慮事項

第10章 美國的學名藥市場:主要的成功因素

第11章 美國的學名藥市場:障礙

第12章 學名藥製造廠房的成立相關要件

  • 製造工程
  • 原料相關要件
  • 機器類·基礎設施相關要件

第13章 美國的學名藥市場:主要企業簡介

  • Teva
  • Mylan
  • Actavis
  • Sandoz
  • Sun Pharma
  • Par Pharmaceuticals
  • Endo Pharmaceuticals
  • Lupin Pharmaceuticals
  • Dr Reddy's
  • Hospira

圖表一覽

目錄
Product Code: SRP00116DP

The US generic drug market has witnessed a transformation over the last three decades. From less than 20% of the total prescriptions, generic drugs now account for the majority of the total prescriptions dispensed in the United States. During 2010-2015, the US generic drug market grew at a CAGR of more than 11% and currently represents a multibillion dollar industry. The biggest catalyst of this industry is the significantly lower price of generics compared to branded drugs. Although generics are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price. This has enabled governments and third-party payers to save billions of dollars in healthcare expenditures and resulted in lower copayments for patients. Other factors such as patent expiration of blockbuster innovator drugs, ageing population and an increasing prevalence of chronic diseases have also acted as catalysts for this market.

The report entitled “US Generic Drug Market - Industry Trends, Competitive Landscape, Opportunities and Outlook” provides a comprehensive insight into the historical and current trends as well as the future prospects of the generic drug market in the United States. This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the US generic drug market. This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the US generic drug market in any form.

What We Have Achieved in This report?

  • Historical, current and future sales trends in the US generic drug market?
  • Historical, current and future prescription trends in the US generic drug market?
  • Performance of the US generic drug market compared to the US pharmaceutical market?
  • Performance of the US generic drug market compared to other major generic drug markets?
  • Structure of the US generic drug market?
  • Competitive landscape in the US generic drug market?
  • Top US generic drug manufacturers and their market shares?
  • Distribution of generic drugs in the US?
  • Top US generic drug distributors and their market shares?
  • Most prescribed generic drugs in the US?
  • Pricing analysis of generic drugs?
  • Value chain analysis of generic drugs in the US?
  • Regulations in the US generic drug market?
  • Manufacturing process of generic drugs?
  • Machinery and raw material requirements for manufacturing generic drugs?
  • Key success and risk factors in the US generic drug market?

Table of Contents

1 Research Methodology and Market Definitions

2 Report Summary

3. US Generic Drug Market-Introduction

  • 3.1. What are Generic Drugs?
  • 3.2. Unbranded and Branded Generics
  • 3.3. Authorized Generics
  • 3.4. Commoditized and Specialty Generics

4. Why is the US Generic Drug Market so Lucrative

  • 4.1. Patent Expiry of Blockbuster Drugs
  • 4.2. Significant Price Differential between Generics and Innovator Drugs
  • 4.3. Savings for the Government and Third Party Payers
  • 4.4. Incentives for Dispensing and Prescribing Generic Drugs
  • 4.5. Reimbursement and Lower Copayments
  • 4.6. Biosimilars

5. Global Generic Drug Market

  • 5.1. Current and Historical Market Trends
  • 5.2. Market Breakup by Country: The United States Represents the World's Biggest Market
  • 5.3. Market Forecast
  • 5.4. Most Prescribed Generic and Branded Drugs

6. US Generic Drug Market

  • 6.1. US Pharmaceutical Market-Current, Historical and Future Market Trends
  • 6.2. US Pharmaceutical Market-Share of Branded and Generic Drugs
  • 6.3. US Generic Drug Market-Current, Historical and Future Volume Trends
  • 6.4. US Generic Drug Market-Current, Historical and Future Sales Trends
  • 6.5. US Generic Drug Market-Market Breakup by Segment

7. US Generic Drug Market- Competitive Landscape

  • 7.1. US Generic Drug Market-Competitive Structure
  • 7.2. US Generic Drug Market-Sales Breakup of Key Players
  • 7.3. US Generic Drug Market-Volume Breakup of Key Players
  • 7.4. US Generic Drug Market-Most Prescribed Generic Drugs
  • 7.5. US Generic Drug Market-Market Breakup by Distribution
  • 7.6. US Generic Drug Market-Pricing Dynamics

8. US Generic Drug Market-Value Chain Analysis

  • 8.1. Research and Development
  • 8.2. Manufacturing
  • 8.3. Marketing and Distribution

9. Regulations in the US Generic Drug Industry

  • 9.1. Overview of Pharmaceutical Regulations
  • 9.2. Drug Applications
  • 9.3. Patents and Market Exclusivity
  • 9.4. Regulatory Requirements for Generic Drugs
  • 9.5. The Hatch-Waxman Act
  • 9.6. Certifications
  • 9.7. Other Important Considerations

10. US Generic Drug Market: Key Success Factors

11. US Generic Drug Market: Road Blocks

12. Requirements for Setting Up a Generic Drug Manufacturing Plant

  • 12.1. Manufacturing Process
  • 12.2. Raw Material Requirements
  • 12.3. Machinery and Infrastructure Requirements

13. US Generic Drug Market-Key Company Profiles

  • 13.1. Teva
  • 13.2. Mylan
  • 13.3. Actavis
  • 13.4. Sandoz
  • 13.5. Sun Pharma
  • 13.6. Par Pharmaceuticals
  • 13.7. Endo Pharmaceuticals
  • 13.8. Lupin Pharmaceuticals
  • 13.9. Dr Reddy's
  • 13.10. Hospira

List of Figures

  • Figure 3-1: Structure of the Pharmaceutical Industry
  • Figure 3-2: Classification of Generic Drugs
  • Figure 4-1: US: Patent Expiry Exposure (in Billion US$), 2009-2018
  • Figure 4-2: US: Savings from Generic Drugs (in Billion US$), 2005-2015
  • Figure 5-1: Global: Generic Drug Market: Sales Value (in Billion US$), 2010-2015
  • Figure 5-2: Global: Generic Drug Market: Sales Volume (in Billion Units), 2010-2015
  • Figure 5-3: Global: Generic Drug Market: Sales Value Breakup by Country (in %), 2015
  • Figure 5-4: Global: Generic Drug Market: Sales Volume Breakup by Country (in %), 2015
  • Figure 5-5: Global: Generic Drug Market Forecast: Sales Value (in Billion US$), 2016-2021
  • Figure 5-6: Global: Generic Drug Market: Sales Volume (in Billion Units), 2016-2021
  • Figure 6-1: US: Pharmaceutical Market: Sales Volume (in Billion Units), 2010-2015
  • Figure 6-2: US: Pharmaceutical Market: Sales Value (in Billion US$), 2010-2015
  • Figure 6-3: US: Pharmaceutical Market Forecast: Sales Value (in Billion US$), 2016-2021
  • Figure 6-4: US: Pharmaceutical Market: Sales Volume (in Billion Units), 2016-2021
  • Figure 6-5: US: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2010 and 2015
  • Figure 6-6: US: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2010 and 2015
  • Figure 6-9: US: Generic Drug Market: Sales Volume (in Billion Units), 2010-2015
  • Figure 6-10: US: Generic Drug Market Forecast: Sales Volume (in Billion Units), 2016-2021
  • Figure 6-7: US: Generic Drug Market: Sales Value (in Billion US$), 2010-2015
  • Figure 6-8: US: Generic Drug Market Forecast: Sales Value (in Billion US$), 2016-2021
  • Figure 6-11: US: Generic Drug Market: Market Breakup by Segment (in %), 2010-2015
  • Figure 7-1: US: Generic Drug Market: Sales Share of Top Players (in %), 2015
  • Figure 7-2: US: Generic Drug Market: Volume Share of Top Players (in %), 2015
  • Figure 7-3: US: Generic Drug Market: Volume Share by Distribution (in %), 2015
  • Figure 7-4: US: Generic Drug Prices as a Percentage of Branded Drug Prices-Based on Number of Competitors
  • Figure 8-1: US: Generic Drug Market: Value Chain Analysis

List of Tables

  • Table 4-1: US: Sales and Patent Expiry of Major Drugs Expected to Lose Patent Protection (in Billion US$)
  • Table 4-2: US: Price Differential between Generics and Innovator Drugs (in %)
  • Table 5-1: Global: Generic Drug Market: Sales Volume and Growth in Major Markets, 2015
  • Table 5-2: Global: Generic Drug Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2015
  • Table 5-3: Global: Branded Drug Market: Volume Performance of Top Branded Drugs (in Million Prescriptions), 2015
  • Table 7-1: US: Generic Drug Market: Sales Performance of Top Players (in Billion US$), 2015
  • Table 7-2: US: Generic Drug Market: Volume Performance of Top Players (in Billion Units), 2015
  • Table 7-3: US: Generics Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2015
  • Table 9-1: US: Overview of Pharmaceutical Regulations
Back to Top